Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures

Re-fracture risk is higher following osteoporotic fracture. However, there is no accurately reported rate of re-fracture incidence in southwest China. The purpose of this study was to describe the osteoporotic vertebral fracture (OVF) survival for re-fracture state and analyze the risk of re-fractur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of bone and mineral metabolism 2019-07, Vol.37 (4), p.722-728
Hauptverfasser: Ma, Xinling, Xia, Haiou, Wang, Jinhua, Zhu, Xiaoxiao, Huang, Fangyan, Lu, Liuxue, He, Lanyan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 728
container_issue 4
container_start_page 722
container_title Journal of bone and mineral metabolism
container_volume 37
creator Ma, Xinling
Xia, Haiou
Wang, Jinhua
Zhu, Xiaoxiao
Huang, Fangyan
Lu, Liuxue
He, Lanyan
description Re-fracture risk is higher following osteoporotic fracture. However, there is no accurately reported rate of re-fracture incidence in southwest China. The purpose of this study was to describe the osteoporotic vertebral fracture (OVF) survival for re-fracture state and analyze the risk of re-fracture. This historical cohort study was conducted in four hospitals in southwest China. Patients aged ≥ 50 years ( n  = 586) with OVF who were supposed to receive anti-osteoporosis drugs after the fracture were included (2012–2017). Telephone follow-up and referring case files were used to estimate the survival for re-fracture and identify the determinants of re-fracture. A total of 555 patients completed the follow-up investigation. Overall, 285 patients experienced a re-fracture, and the longest follow-up investigation time was 72 months. The survival rates for re-fracture at 12 months, 24 months, 36 months, and 48 months were 82.0%, 71.5%, 61.7%, and 34.0%, respectively. The factors correlated with re-fracture hazard were advanced age [hazard ratio (HR) = 1.996], being female (HR = 1.342), smoking (HR = 1.435), history of hypertension (HR = 1.219) and diabetes (HR = 3.271), and persistence of taking anti-osteoporosis drugs after fracture [0–3 months, 4–6 months, 7–12 months, and more than 12 months (HR = 0.703)]. OVF patients with advanced age, who were female, smoked, had fracture with hypertension or diabetes, and who complied poorly with anti-osteoporosis drug treatment presented higher prevalence of re-fracture and low anti-osteoporosis adherence in southwest China. The management of anti-osteoporosis after fracture is necessary in this area.
doi_str_mv 10.1007/s00774-018-0974-4
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179228245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2136320630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-edb0bec882b70045e334a9051ee465cce80496bb821bc6cee71d8f94428f6ef43</originalsourceid><addsrcrecordid>eNp1kEtr3TAQhUVJaW7S_oBsgiCbbpyOHrakZQhtEwgESrvoSsjyOHHiazmS3NJ_X12cBwSy0QjON2cOh5AjBqcMQH1J5VGyAqYrMOUj35ENk6Ku6gbkHtmAYbLSSpl9cpDSHQBTtWIfyL4A2dRF3ZDfP7Dqo_N5iUjd1FEfYsTRZexoHNI97YsWYqLDRGeXB5xyon-HfEtDyhjmEEMePP2DMWMb3UifzNJH8r53Y8JPj_OQ_Pr29ef5RXV1_f3y_Oyq8sI0ucKuhRa91rxVALJGIaQzUDPEktF71CBN07aas9Y3HlGxTvdGSq77BnspDsnn1XeO4WHBlO12SB7H0U0YlmQ5U4ZzzWVd0JNX6F1Y4lTSFUo0gkMjoFBspXwMKUXs7RyHrYv_LAO7692uvdvSu931bnchjh-dl3aL3fPGU9EF4CuQijTdYHw5_bbrfy1HjlQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2136320630</pqid></control><display><type>article</type><title>Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>Ma, Xinling ; Xia, Haiou ; Wang, Jinhua ; Zhu, Xiaoxiao ; Huang, Fangyan ; Lu, Liuxue ; He, Lanyan</creator><creatorcontrib>Ma, Xinling ; Xia, Haiou ; Wang, Jinhua ; Zhu, Xiaoxiao ; Huang, Fangyan ; Lu, Liuxue ; He, Lanyan</creatorcontrib><description>Re-fracture risk is higher following osteoporotic fracture. However, there is no accurately reported rate of re-fracture incidence in southwest China. The purpose of this study was to describe the osteoporotic vertebral fracture (OVF) survival for re-fracture state and analyze the risk of re-fracture. This historical cohort study was conducted in four hospitals in southwest China. Patients aged ≥ 50 years ( n  = 586) with OVF who were supposed to receive anti-osteoporosis drugs after the fracture were included (2012–2017). Telephone follow-up and referring case files were used to estimate the survival for re-fracture and identify the determinants of re-fracture. A total of 555 patients completed the follow-up investigation. Overall, 285 patients experienced a re-fracture, and the longest follow-up investigation time was 72 months. The survival rates for re-fracture at 12 months, 24 months, 36 months, and 48 months were 82.0%, 71.5%, 61.7%, and 34.0%, respectively. The factors correlated with re-fracture hazard were advanced age [hazard ratio (HR) = 1.996], being female (HR = 1.342), smoking (HR = 1.435), history of hypertension (HR = 1.219) and diabetes (HR = 3.271), and persistence of taking anti-osteoporosis drugs after fracture [0–3 months, 4–6 months, 7–12 months, and more than 12 months (HR = 0.703)]. OVF patients with advanced age, who were female, smoked, had fracture with hypertension or diabetes, and who complied poorly with anti-osteoporosis drug treatment presented higher prevalence of re-fracture and low anti-osteoporosis adherence in southwest China. The management of anti-osteoporosis after fracture is necessary in this area.</description><identifier>ISSN: 0914-8779</identifier><identifier>EISSN: 1435-5604</identifier><identifier>DOI: 10.1007/s00774-018-0974-4</identifier><identifier>PMID: 30465091</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Aged ; China ; Cohort Studies ; Diabetes ; Diabetes mellitus ; Female ; Follow-Up Studies ; Fractures ; Health risk assessment ; Humans ; Hypertension ; Male ; Medicine ; Medicine &amp; Public Health ; Metabolic Diseases ; Multivariate Analysis ; Original Article ; Orthopedics ; Osteoporosis ; Osteoporotic Fractures - complications ; Osteoporotic Fractures - epidemiology ; Patients ; Proportional Hazards Models ; Risk Factors ; Smoking ; Spinal Fractures - complications ; Spinal Fractures - epidemiology ; Survival ; Vertebrae</subject><ispartof>Journal of bone and mineral metabolism, 2019-07, Vol.37 (4), p.722-728</ispartof><rights>The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2018</rights><rights>Journal of Bone and Mineral Metabolism is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-edb0bec882b70045e334a9051ee465cce80496bb821bc6cee71d8f94428f6ef43</citedby><cites>FETCH-LOGICAL-c396t-edb0bec882b70045e334a9051ee465cce80496bb821bc6cee71d8f94428f6ef43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00774-018-0974-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00774-018-0974-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30465091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Xinling</creatorcontrib><creatorcontrib>Xia, Haiou</creatorcontrib><creatorcontrib>Wang, Jinhua</creatorcontrib><creatorcontrib>Zhu, Xiaoxiao</creatorcontrib><creatorcontrib>Huang, Fangyan</creatorcontrib><creatorcontrib>Lu, Liuxue</creatorcontrib><creatorcontrib>He, Lanyan</creatorcontrib><title>Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures</title><title>Journal of bone and mineral metabolism</title><addtitle>J Bone Miner Metab</addtitle><addtitle>J Bone Miner Metab</addtitle><description>Re-fracture risk is higher following osteoporotic fracture. However, there is no accurately reported rate of re-fracture incidence in southwest China. The purpose of this study was to describe the osteoporotic vertebral fracture (OVF) survival for re-fracture state and analyze the risk of re-fracture. This historical cohort study was conducted in four hospitals in southwest China. Patients aged ≥ 50 years ( n  = 586) with OVF who were supposed to receive anti-osteoporosis drugs after the fracture were included (2012–2017). Telephone follow-up and referring case files were used to estimate the survival for re-fracture and identify the determinants of re-fracture. A total of 555 patients completed the follow-up investigation. Overall, 285 patients experienced a re-fracture, and the longest follow-up investigation time was 72 months. The survival rates for re-fracture at 12 months, 24 months, 36 months, and 48 months were 82.0%, 71.5%, 61.7%, and 34.0%, respectively. The factors correlated with re-fracture hazard were advanced age [hazard ratio (HR) = 1.996], being female (HR = 1.342), smoking (HR = 1.435), history of hypertension (HR = 1.219) and diabetes (HR = 3.271), and persistence of taking anti-osteoporosis drugs after fracture [0–3 months, 4–6 months, 7–12 months, and more than 12 months (HR = 0.703)]. OVF patients with advanced age, who were female, smoked, had fracture with hypertension or diabetes, and who complied poorly with anti-osteoporosis drug treatment presented higher prevalence of re-fracture and low anti-osteoporosis adherence in southwest China. The management of anti-osteoporosis after fracture is necessary in this area.</description><subject>Aged</subject><subject>China</subject><subject>Cohort Studies</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fractures</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Diseases</subject><subject>Multivariate Analysis</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteoporosis</subject><subject>Osteoporotic Fractures - complications</subject><subject>Osteoporotic Fractures - epidemiology</subject><subject>Patients</subject><subject>Proportional Hazards Models</subject><subject>Risk Factors</subject><subject>Smoking</subject><subject>Spinal Fractures - complications</subject><subject>Spinal Fractures - epidemiology</subject><subject>Survival</subject><subject>Vertebrae</subject><issn>0914-8779</issn><issn>1435-5604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kEtr3TAQhUVJaW7S_oBsgiCbbpyOHrakZQhtEwgESrvoSsjyOHHiazmS3NJ_X12cBwSy0QjON2cOh5AjBqcMQH1J5VGyAqYrMOUj35ENk6Ku6gbkHtmAYbLSSpl9cpDSHQBTtWIfyL4A2dRF3ZDfP7Dqo_N5iUjd1FEfYsTRZexoHNI97YsWYqLDRGeXB5xyon-HfEtDyhjmEEMePP2DMWMb3UifzNJH8r53Y8JPj_OQ_Pr29ef5RXV1_f3y_Oyq8sI0ucKuhRa91rxVALJGIaQzUDPEktF71CBN07aas9Y3HlGxTvdGSq77BnspDsnn1XeO4WHBlO12SB7H0U0YlmQ5U4ZzzWVd0JNX6F1Y4lTSFUo0gkMjoFBspXwMKUXs7RyHrYv_LAO7692uvdvSu931bnchjh-dl3aL3fPGU9EF4CuQijTdYHw5_bbrfy1HjlQ</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Ma, Xinling</creator><creator>Xia, Haiou</creator><creator>Wang, Jinhua</creator><creator>Zhu, Xiaoxiao</creator><creator>Huang, Fangyan</creator><creator>Lu, Liuxue</creator><creator>He, Lanyan</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190701</creationdate><title>Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures</title><author>Ma, Xinling ; Xia, Haiou ; Wang, Jinhua ; Zhu, Xiaoxiao ; Huang, Fangyan ; Lu, Liuxue ; He, Lanyan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-edb0bec882b70045e334a9051ee465cce80496bb821bc6cee71d8f94428f6ef43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>China</topic><topic>Cohort Studies</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fractures</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Diseases</topic><topic>Multivariate Analysis</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteoporosis</topic><topic>Osteoporotic Fractures - complications</topic><topic>Osteoporotic Fractures - epidemiology</topic><topic>Patients</topic><topic>Proportional Hazards Models</topic><topic>Risk Factors</topic><topic>Smoking</topic><topic>Spinal Fractures - complications</topic><topic>Spinal Fractures - epidemiology</topic><topic>Survival</topic><topic>Vertebrae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Xinling</creatorcontrib><creatorcontrib>Xia, Haiou</creatorcontrib><creatorcontrib>Wang, Jinhua</creatorcontrib><creatorcontrib>Zhu, Xiaoxiao</creatorcontrib><creatorcontrib>Huang, Fangyan</creatorcontrib><creatorcontrib>Lu, Liuxue</creatorcontrib><creatorcontrib>He, Lanyan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of bone and mineral metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Xinling</au><au>Xia, Haiou</au><au>Wang, Jinhua</au><au>Zhu, Xiaoxiao</au><au>Huang, Fangyan</au><au>Lu, Liuxue</au><au>He, Lanyan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures</atitle><jtitle>Journal of bone and mineral metabolism</jtitle><stitle>J Bone Miner Metab</stitle><addtitle>J Bone Miner Metab</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>37</volume><issue>4</issue><spage>722</spage><epage>728</epage><pages>722-728</pages><issn>0914-8779</issn><eissn>1435-5604</eissn><abstract>Re-fracture risk is higher following osteoporotic fracture. However, there is no accurately reported rate of re-fracture incidence in southwest China. The purpose of this study was to describe the osteoporotic vertebral fracture (OVF) survival for re-fracture state and analyze the risk of re-fracture. This historical cohort study was conducted in four hospitals in southwest China. Patients aged ≥ 50 years ( n  = 586) with OVF who were supposed to receive anti-osteoporosis drugs after the fracture were included (2012–2017). Telephone follow-up and referring case files were used to estimate the survival for re-fracture and identify the determinants of re-fracture. A total of 555 patients completed the follow-up investigation. Overall, 285 patients experienced a re-fracture, and the longest follow-up investigation time was 72 months. The survival rates for re-fracture at 12 months, 24 months, 36 months, and 48 months were 82.0%, 71.5%, 61.7%, and 34.0%, respectively. The factors correlated with re-fracture hazard were advanced age [hazard ratio (HR) = 1.996], being female (HR = 1.342), smoking (HR = 1.435), history of hypertension (HR = 1.219) and diabetes (HR = 3.271), and persistence of taking anti-osteoporosis drugs after fracture [0–3 months, 4–6 months, 7–12 months, and more than 12 months (HR = 0.703)]. OVF patients with advanced age, who were female, smoked, had fracture with hypertension or diabetes, and who complied poorly with anti-osteoporosis drug treatment presented higher prevalence of re-fracture and low anti-osteoporosis adherence in southwest China. The management of anti-osteoporosis after fracture is necessary in this area.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>30465091</pmid><doi>10.1007/s00774-018-0974-4</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0914-8779
ispartof Journal of bone and mineral metabolism, 2019-07, Vol.37 (4), p.722-728
issn 0914-8779
1435-5604
language eng
recordid cdi_proquest_miscellaneous_2179228245
source MEDLINE; Springer Online Journals
subjects Aged
China
Cohort Studies
Diabetes
Diabetes mellitus
Female
Follow-Up Studies
Fractures
Health risk assessment
Humans
Hypertension
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Multivariate Analysis
Original Article
Orthopedics
Osteoporosis
Osteoporotic Fractures - complications
Osteoporotic Fractures - epidemiology
Patients
Proportional Hazards Models
Risk Factors
Smoking
Spinal Fractures - complications
Spinal Fractures - epidemiology
Survival
Vertebrae
title Re-fracture and correlated risk factors in patients with osteoporotic vertebral fractures
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A06%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Re-fracture%20and%20correlated%20risk%20factors%20in%20patients%20with%20osteoporotic%20vertebral%20fractures&rft.jtitle=Journal%20of%20bone%20and%20mineral%20metabolism&rft.au=Ma,%20Xinling&rft.date=2019-07-01&rft.volume=37&rft.issue=4&rft.spage=722&rft.epage=728&rft.pages=722-728&rft.issn=0914-8779&rft.eissn=1435-5604&rft_id=info:doi/10.1007/s00774-018-0974-4&rft_dat=%3Cproquest_cross%3E2136320630%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2136320630&rft_id=info:pmid/30465091&rfr_iscdi=true